Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations.

Weinkove R, George P, Dasyam N, McLellan AD. · 2019

Read Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations. by Weinkove R, George P, Dasyam N, McLellan AD. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6511336.txt.

Introduction

Weinkove and co-authors review costimulatory domains in chimeric antigen receptor design. Their review appeared in Clinical & Translational Immunology. CAR T cells need costimulatory signals to expand and persist. Designers build those signals into the receptor itself. They borrow domains from molecules such as CD28 or 4-1BB.

Choice and position of a domain shape how the cells behave. Clinical work on anti-CD19 CAR T cells hints at distinct effects. Domains differ in cell kinetics, killing power and safety. The authors compare set domains such as ICOS, OX40 and CD27. They also weigh pairs of domains. Clear winners may depend on the construct and the disease.

Catalog record

CREATORWeinkove R, George P, Dasyam N, McLellan AD.
YEAR2019
COLLECTIONPAPERS
FORMATTXT
FILE SIZE57 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6511336

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations By Robert Weinkove, Philip George, Nathaniel Dasyam, Alexander D McLellan Published in: Clinical & Translational Immunology DOI: 10.1002/cti2.1049 ABSTRACT Abstract Costimulatory signals are required to achieve robust chimeric antigen receptor (CAR) T cell expansion, function, persistence and antitumor activity. These can be provided by incorporating intracellular signalling domains from one or more T cell costimulatory molecules, such as CD28 or 4‐1BB, into the CAR. The selection and positioning of costimulatory domains within a CAR construct influence CAR T cell function and fate, and clinical experience of autologous anti‐CD19 CAR T cell therapies suggests that costimulatory domains have differential impacts on CAR T cell kinetics, cytotoxic function and potentially safety profile. The clinical impacts of combining costimulatory domains and of alternative costimulatory domains are not yet clearly established, and may be construct‐ and disease‐specific. The aim of this review is to summarise the function and effect of established and emerging costimulatory domains and their combinations within CAR T cells. Keywords: immunology, immunotherapy, lymphocytes, T cells T CELL COSTIMULATION Antigen‐specific activation of T lymphocytes (T cells) relies on interactions between T cell receptors (TCRs) and their cognate antigens, which lead to TCR aggregation, phosphorylation of TCR‐associated CD3 proteins and downstream intracellular signalling.1 However, the strength and quality of a T cell response to antigen is highly dependent on signalling by an array of costimulatory and co‐inhibitory receptors also expressed on the T cell surface.2 Costimulatory signals enhance T cell proliferation, cytokine secretion, cytotoxic function, memory formation or survival. In contrast, co‐inhibitory signals inhibit T cell proliferation and function and can lead to tolerance, exhaustion and T cell apoptosis.1 As early as 1975, Lafferty and Cunningham2 proposed that in addition to antigenic stimuli, full activation of antigen‐specific T cells required secondary signals from antigen‐presenting cells (APCs). Confirmation of this classical two‐signal hypothesis was achieved with the generation of antibodies that block costimulatory molecules, and the cloning of B7 family members CD80 and CD86, which are ligands for the prototypical T cell costimulatory receptor CD28.3 Later observations confirmed that antigenic stimulation without sufficient costimulation results in T cell anergy and T cell susceptibility to activation‐induced cell death (AICD).3 Broadly defined as cell surface molecules that can transduce signals into T cells to enhance TCR‐mediated signals,1 most costimulatory receptors belong to the immunoglobulin (Ig) or tumor necrosis factor receptor (TNFR) superfamilies, and bind to ligands expressed by activated or licensed APCs.3, 4 Costimulatory receptors of the Ig superfamily tend to activate phosphatidylinositol 3‐kinase (PI3K) leading to protein kinase B (Akt) and downstream nuclear factor κB (NF‐κB) activation, while TNFR superfamily members preferentially recruit and activate TNF receptor‐associated factors (TRAFs) to potentiate NF‐κB activation.3, 4 Examples of costimulatory molecules expressed by T cells include CD28, ICOS, CD27, 4‐1BB, OX40 and CD40L (see Table 1). The degree of costimulation received by a T cell is modulated by T cell surface expression of costimulatory molecules, expression of their ligands on APCs and T cell expression of co‐inhibitory receptors, many of which compete with costimulatory receptors for the same ligands. In physiological and infectious disease settings, costimulatory signals are delivered by APCs in response to danger signals, such as pathogen‐associated molecular patterns, or stressed or necrotic cells, or in response to ‘licensing’ of peptide‐presenting APCs by CD4+ T‐helper cells.1, 3 Mice lacking key costimulatory receptors, such as CD28 or 4‐1BB, exhibit defects in T cell function.3, 5 In contrast, monoclonal antibodies that either activate T cell costimulatory receptors or block co‐inhibitory receptor signalling can enhance T cell responses against cancer.3, 6 However, activation of costimulatory receptors can lead to unbridled inflammatory responses with life‐threatening consequences.7 An understanding of T cell costimulation is therefore critical for the development of safe and effective adoptive T cell therapies, including those employing chimeric antigen receptors CARs. [Table: Costimulatory molecules employed within chimeric antigen receptor (CARs)] COSTIMULATORY DOMAINS WITHIN CHIMERIC ANTIGEN RECEPTORS Synthetic ‘CARs’ represent a major advance in adoptive T cell therapy. By combining the variable regions of a high‐affinity monoclonal antibody with intracellular signalling components derived from the TCR complex, CARs allow redirection of T cell cytotoxicity against an antigen of choice, entirely independently of target cell major histocompatibility complex (MHC) expression. For discussion purposes, in this section, the first domain (including the transmembrane (TM), domain) listed is that closest to the membrane, and the last is at the cytoplasmic tail. Initial CAR designs incorporated the variable regions of a monoclonal antibody fused to the TCR α‐ and β‐chains.8, 9 Subsequently, modified versions utilised an ‘ectodomain’ of single‐chain variable fragment (scFv), a transmembrane domain and an ‘endodomain’ incorporating immunoreceptor tyrosine‐based activation motif (ITAM)‐replete FcγR or CD3‐ζ domains.10 The scFv is typically of high affinity for the corresponding antigen and contributes to observed differences in signalling between conventional TCRs and CAR constructs. This basic structure has formed the basis for modern CAR design. T cells genetically modified to express CARs incorporating intracellular CD3ζ alone, now termed ‘first‐generation’ CARs, are activated by and exhibit cytotoxicity against target cells expressing the CAR target, but failed to proliferate well or to elicit long‐term antitumor responses.11 Incorporation of the intracellular signalling domain of CD28 into a CAR improved T cell proliferation and cytokine production.12, 13 Figure 1 contrasts costimulation of unmodified T cells with CAR T cell costimulation. Incorporating a costimulatory receptor domain into the CAR itself, rather than within a separate transgene, or relying on costimulatory ligand expression by endogenous cells has distinct advantages: (1) a single polypeptide CAR incorporating only the intracellular signalling domain of the costimulatory molecule(s) is required, retaining a parsimonious transgene size, (2) costimulatory signalling is restricted to T cells both expressing the CAR and exposed to target antigen, and (3) costimulatory signals are provided independently of tumor or microenvironment expression of costimulatory receptor ligands. [Figure: Costimulation in unmodified T cells and within chimeric antigen receptor (CAR) T cells. (a) T cells express a TCR specific for peptide in the context of major histocompatibility complex. Costimulation eliciting optimal T cell activity, proliferation and survival requires expression of costimulatory receptor ligands such as CD80 and CD86 on APCs. (b) T cells transduced to present a CAR incorporating an intracellular costimulatory domain, such as that of CD28, can undergo potent activation upon exposure to cells expressing the target antigen without target cell expression of costimulatory receptor ligands. Since CAR costimulatory domains lack the original costimulator extracellular structures, they are unable to transmit negative signals from inhibitory ligands.] Following initial demonstrations that the CD28 domain within CARs was effective in providing costimulation, a range of other costimulatory domains have been assessed, including another Ig superfamily member, ICOS, and the TNFR superfamily members 4‐1BB, OX40 and CD27.14, 15 The use of costimulatory domains has since expanded from those derived from members of the Ig and TNFR superfamilies, to others signalling via cytoplasmic domains of IL‐2Rβ, IL‐15R‐α, CD40 or MyD88.16, 17 The incorporation of different costimulatory molecules into CARs may be expected to confer varying degrees of costimulatory domain‐specific activation, potentially with distinct impacts on CAR T cell activity, proliferation and fate (Figure 2). [Figure: Generalised mechanism of chimeric antigen receptor (CAR) signalling provided by CD3‐ζ ITAMs and a costimulator domain. Ligation of the CAR scFv

Read the complete text